Rodino-Klapac replacing O’Neill as Sarepta’s R&D head

Louise Rodino-Klapac will take on the role of head of R&D at Sarepta Therapeutics Inc. (NASDAQ:SRPT) on Dec. 1, adding to her current responsibilities as EVP and CSO. Gilmore O’Neill, the current head of R&D, will leave the company at the end of November after a tenure of three years. The company’s stock fell 50% in January after its Duchenne muscular dystrophy gene therapy candidate missed in Phase II.

Antibody therapeutics company Lassen Therapeutics hired Puneet Arora as CMO. Arora previously served as the head of clinical, inflammation and immunology at Principia Biopharma...